98 related articles for article (PubMed ID: 27522525)
1. Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation.
Sládková V; Dammer O; Kratochvíl B
J Pharm Sci; 2016 Oct; 105(10):3136-3142. PubMed ID: 27522525
[TBL] [Abstract][Full Text] [Related]
2. Crystal Structure Analysis of the First Discovered Stability-Enhanced Solid State of Tenofovir Disoproxil Free Base Using Single Crystal X-ray Diffraction.
An JH; Kiyonga AN; Yoon W; Ryu HC; Kim JS; Kang C; Park M; Yun H; Jung K
Molecules; 2017 Jul; 22(7):. PubMed ID: 28708115
[TBL] [Abstract][Full Text] [Related]
3. Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.
Watkins ME; Wring S; Randolph R; Park S; Powell K; Lutz L; Nowakowski M; Ramabhadran R; Domanico PL
J Pharm Sci; 2017 Mar; 106(3):906-919. PubMed ID: 27986599
[TBL] [Abstract][Full Text] [Related]
4. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.
Golla VM; Kurmi M; Shaik K; Singh S
J Pharm Biomed Anal; 2016 Nov; 131():146-155. PubMed ID: 27589032
[TBL] [Abstract][Full Text] [Related]
5. Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: physicochemical, molecular, microstructural, and stability evaluation.
Pokharkar VB; Jolly MR; Kumbhar DD
Eur J Pharm Sci; 2015 Apr; 71():99-111. PubMed ID: 25708940
[TBL] [Abstract][Full Text] [Related]
6. Organic vapor sorption method of isostructural solvates and polymorph of tenofovir disoproxil fumarate.
Lee J; Boerrigter SX; Jung YW; Byun Y; Yuk SH; Byrn SR; Lee EH
Eur J Pharm Sci; 2013 Nov; 50(3-4):253-62. PubMed ID: 23872626
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of mucoadhesive vaginal tablets of tenofovir disoproxil fumarate for pre-exposure prophylaxis of HIV.
Khan AB; Thakur RS
Drug Dev Ind Pharm; 2018 Mar; 44(3):472-483. PubMed ID: 29082767
[TBL] [Abstract][Full Text] [Related]
8. Development of novel tenofovir disoproxil phosphate salt with stability enhancement and bioequivalence to the commercial tenofovir disoproxil fumarate salt in rats and beagle dogs.
Cho JH; Choi HG
Int J Pharm; 2020 Feb; 576():118957. PubMed ID: 31843551
[TBL] [Abstract][Full Text] [Related]
9. Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats.
Shailender J; Ravi PR; Saha P; Myneni S
Xenobiotica; 2017 Dec; 47(12):1104-1111. PubMed ID: 27921450
[TBL] [Abstract][Full Text] [Related]
10. Crystalline solid dispersion-a strategy to slowdown salt disproportionation in solid state formulations during storage and wet granulation.
Nie H; Xu W; Taylor LS; Marsac PJ; Byrn SR
Int J Pharm; 2017 Jan; 517(1-2):203-215. PubMed ID: 27979765
[TBL] [Abstract][Full Text] [Related]
11. How tenofovir disoproxil fumarate can impact on solubility and dissolution rate of efavirenz?
Bazzo GC; Mostafa D; França MT; Pezzini BR; Stulzer HK
Int J Pharm; 2019 Oct; 570():118597. PubMed ID: 31401297
[TBL] [Abstract][Full Text] [Related]
12. Development of stabilized tenofovir disoproxil tablet: degradation profile, stabilization, and bioequivalence in beagle dogs.
Oh GH; Kim JE; Park YJ
Drug Dev Ind Pharm; 2018 May; 44(5):757-766. PubMed ID: 29198140
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11.
Tun-Yhong W; Chinpaisal C; Pamonsinlapatham P; Kaewkitichai S
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167562
[TBL] [Abstract][Full Text] [Related]
14. Stability behaviour of antiretroviral drugs and their combinations. 3: Characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry.
Kurmi M; Singh DK; Tiwari S; Sharma P; Singh S
J Pharm Biomed Anal; 2016 Sep; 128():438-446. PubMed ID: 27344633
[TBL] [Abstract][Full Text] [Related]
15. Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry.
Kurmi M; Kushwah BS; Sahu A; Narayanam M; Singh S
J Pharm Biomed Anal; 2016 Jun; 125():245-59. PubMed ID: 27042808
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
17. Impact of Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State Formulations.
Nie H; Xu W; Ren J; Taylor LS; Marsac PJ; John CT; Byrn SR
Mol Pharm; 2016 Oct; 13(10):3541-3552. PubMed ID: 27542728
[TBL] [Abstract][Full Text] [Related]
18. Excipient Stability in Oral Solid Dosage Forms: A Review.
Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
[TBL] [Abstract][Full Text] [Related]
19. Leveraging ToF-SIMS imaging to investigate tenofovir disoproxil fumarate degradation at excipient interfaces in oral compressed tablets.
Topolski JE; Sheng H; Moore C; Rading D; Moyer TB; Punia A; Lamm MS; Pierson E
J Pharm Biomed Anal; 2024 Feb; 239():115863. PubMed ID: 38056285
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
